about
Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 studyInvolved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin'sNew insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling.Antibodies in the diagnosis of coeliac disease: a biopsy-controlled, international, multicentre study of 376 children with coeliac disease and 695 controls.Impact of age on the efficacy of bone marrow mononuclear cell transplantation in experimental stroke.Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing.A Multicenter Trial of Remote Ischemic Preconditioning for Heart Surgery.Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin's LymphomaSignificant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the D[18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma.Risk-adapted monitoring is not inferior to extensive on-site monitoring: Results of the ADAMON cluster-randomised study.Validation of Antibody-Based Strategies for Diagnosis of Pediatric Celiac Disease Without Biopsy.Modeling combined chemo- and immunotherapy of high-grade non-Hodgkin lymphoma.GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma.Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma.
P50
Q28287750-674FA5F2-A0B6-449F-8B54-50B538194A60Q33349465-B9580CE1-A1B8-448F-ADBE-1FE24A2B5EFBQ33392210-D6342F05-B51B-4B96-9F02-8A63FA216132Q33618453-93B0A265-5784-4D53-B809-D1EC539E210FQ34392864-E2B19FF7-D157-453D-8172-79D20CBE97A6Q34473466-410AB8B2-7E10-46EE-9450-EB1CC115A390Q34496763-9A202AFC-ED0E-4331-8760-5040B39E68D1Q34524632-171FC0AE-4AB4-471C-86E1-B8BD17274A8FQ34534439-C1F7B555-62FC-427D-BF0A-F2934E69966CQ34580808-47F38E3E-D808-4220-A342-3A8912B63031Q34611141-81A2CEC7-1361-4724-BBFB-BB8BF4BF3F57Q35030096-07CA46E7-493C-4BAD-BEDC-8FB86D39A435Q35952736-C2C2C5CC-5425-481C-A02A-217F35A69F60Q37473480-DEB7DC0F-043B-4349-8615-4198C8DDF0C2Q37913782-8779B613-F54F-4C24-8AD6-4AB379866802Q38635306-29A815B6-8DA9-4D03-A040-37A776292F68Q38810377-CD32BC82-7EFD-448B-9CDC-2E5E00BD4B2AQ38932141-EA90295C-EAD7-43AF-8243-6A008A7726F1Q39915264-2C85CAD2-F3E7-40D0-B74C-16787C59498DQ40680175-2BA67AC0-694B-4BD8-8173-199911D55F56
P50
description
onderzoeker
@nl
name
Dirk Hasenclever
@ast
Dirk Hasenclever
@en
Dirk Hasenclever
@es
Dirk Hasenclever
@sl
type
label
Dirk Hasenclever
@ast
Dirk Hasenclever
@en
Dirk Hasenclever
@es
Dirk Hasenclever
@sl
prefLabel
Dirk Hasenclever
@ast
Dirk Hasenclever
@en
Dirk Hasenclever
@es
Dirk Hasenclever
@sl